Drugs in development for hepatitis B

Drugs

Volumn 65, Issue 11, 2005, Pages 1451-1460

  Buti, Maria ^a   Esteban, Rafael ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; DEOXYADENOSINE; EMTRICITABINE; ENTECAVIR; GUANOSINE DERIVATIVE; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOSIDE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR DISOPROXIL; TORCITABINE; VALTORCITABINE;

CLINICAL TRIAL; DRUG COST; DRUG POTENCY; DRUG SAFETY; DRUG USE; HEPATITIS B; HUMAN; PATIENT; REVIEW; SIDE EFFECT; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; DEOXYCYTIDINE; GUANINE; HEPATITIS B; HUMANS; INTERFERON ALFA-2A; NUCLEOSIDES; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS;

HEPATITIS B VIRUS;

EID: 23744445119     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565110-00001     Document Type: Review

References (53)

1. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003; 39 Suppl. 1: S3-25
2. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-53
3. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24
4. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-41
5. Hoofnagle JH, Dusheiko GM, Seeff LB, et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744-8
6. Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-72
7. Yang H-I, Lu S-N, Liaw Y-F, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74
8. Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Vir Hep Rev 1995; 1: 7-36
9. Hunt CM, McGill JM, Allen ML, et al. Clinical relevance of hepatitis B virus mutations. Hepatology 2000; 31: 1037-44
10. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268-73
11. Brunetto MR, Giarin M, Oliveri F, et al. Wild type and e antigen-minus hepatitis B virus in course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88: 4186-90
12. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305
13. Janssen HLA, von Zonneveld M, Senturk H, et al. Pegylated interferon α-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005 Jan 8; 365 (9454): 123-9
14. Lau G, Piratvisuth T, Luo KX, et al. Peginterferon alfa2a monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study. Hepatology 2004; 40 Suppl. 1: 171A
15. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon-alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17
16. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999; 43: 190-3
17. Nevens F, de Man RA, Chua D, et al. Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B [abstract]. Hepatology 2000; 32 Suppl.: 377A
18. Lai C-L, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B. Gastroenterology 2002; 123: 1831-8
19. de Man RA, Wolters L, Nevens F, et al. A study of oral entecavir given for 28 days in both treatment-naive and pre-treated subjects with chronic hepatitis [abstract]. Hepatology 2000; 32 Suppl.: 376A
20. Tassopoulos N, Hadziyannis S, Cianciara J, et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy [abstract]. Hepatology 2001; 34: 340A
21. Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg positive chronic hepatitis B: results of phase III study ETV-022 in nuclesoide naive patients [abstract]. Hepatology 2004; 40 Suppl. 1: 193A
22. Shouval D, Lai CLL, Cheinquer H, et al. Entecavir demosntrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg-negative chronic hepatitis B: results of phase III trial ETV-027 [abstract]. Hepatology 2004; 40 Suppl. 1: 728A
23. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HbeAg-positive chronic hepatitis B: results of phase III study ETV-026 [abstract]. Hepatology 2004; 40 Suppl. 1: 664A
24. Delanay WE, Yang H, Sabogal A, et al. In vitro cross-resistance testing of adefovir, lamivudine, telvibudine, entecavir and other anti-HBV compounds against four major mutational patterns of lamivudine-resistant HBV [abstract]. Hepatology 2004; 40 Suppl. 1: 244A
25. Korba BE, Schinazi RF, Cote P, et al. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother 2000; 44: 1757-60
26. Ladner SK, Miller TJ, Otto MJ, et al. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antiviral Chemother 1998; 9: 65-72
27. Wang C, Correy L, Leung N, et al. Antiviral activity of 48 weeks of emtricitabine (FTC) treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B (CHB) [abstract]. Hepatology 2001; 34: 323A
28. Shiffman ML, Ng TM, Krastev Z, et al. A double-blind, placebo-controlled trial of emtrcitabine (FTC, Emtriva) administered once-daily for treatment of chronic Hepatitis B virus infection [abstract]. Hepatology 2004; 40 Suppl. 1: 172A
29. Lau G, Cooksley H, Ribeiro RM, et al. Randomized, double, blind study comparing adefovir dipivoxil plus emtricitabine combination therapy versus adefovir alone in HBeAg-positive chronic hepatitis B: efficacy and mechanisms of treatment response [abstract]. Hepatology 2004; 40 Suppl. 1: 272A
30. Han SH, Leung NWY, Teo EK, et al. Results of a one-year international phase IIb trial of LdT, and LdT plus lamivudine in patients with chronic hepatitis B [abstract]. Hepatology 2004; 40 Suppl. 1: 16
31. Chu CK, Boudinot FD, Peek SF, et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998; 3 Suppl. 3: 113-21
32. Peek SF, Cote PJ, Jacob JR, et al. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, l-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001; 33: 254-66
33. Abdelhamed AM, Kelley CM, Miller TG, et al. Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay. Antimicrob Agents Chemother 2003; 47: 324-36
34. Marcellin P, Mommeja-Marin H, Sacks SL, et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-8
35. Marcellin P, Leung N, Hann H-WL, et al. A phase II, random zed trial evaluating the safety, pharmacokinetics and antiviral activity of clevudine for 12 weeks in patients with chronic hepatitis B [abstract]. Hepatology 2004; 40 Suppl. 1: 652A
36. Benhamou Y, Poynard T. Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus. J Hepatol 2003; 39 Suppl. 1: S194-9
37. Lessells R, Leen C. Management of hepatitis B in patients coinfected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 2004; 23: 366-74
38. Benhamou Y. Antiretroviral therapy and HIV/hepatitis B virus coinfection. Clin Infect Dis 2004; 38 Suppl. 2: S98-103
39. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-92
40. Lerbaek A, Kristiansen TB, Katzenstein TL, et al. Tenofovir treatment in an unselected cohort of highly antiretroviral experienced HIV positive patients. Scand J Infect Dis 2004; 36: 280-6
41. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001; 358: 718-23
42. Van Bömmel F, Wünche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant Hepatitios B virus infection. Hepatology 2004; 40: 1421-5
43. Standring DN, Bridges EG, Placidi L, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother 2003; 12 Suppl. 1: 119-29
44. Bryant ML, Bridges EG, Placidi L, et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother 2001; 45: 229-35
45. le Guehier F, Pichoud C, Jamard C, et al. Characterization of the antiviral effect of 2′3′-dideoxy-2′-3′didehydro-beta-L- 5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000; 44: 111-22
46. Delaney W, Yang H, Miller M, et al. Lamivudine-resistant HBV is cross-resistant to L-dT and L-dC in vitro. J Hepatol 2002; 36 Suppl. 1: 89
47. Lai C-L, Lim SG, Brown NA, et al. A dose-finding study of once-daily oral telvivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 2004; 40: 719-26
48. Lai C-L, Leung NWY, Teo E-K, et al. Results of a one-year international phase IIb comparative trial of telbivudine, lamivudine, and the combination, in patients with chronic hepatitis B [abstract]. Hepatology 2003; 38 Suppl. 1: 262A
49. Neumman AV, Zhou XJ, Boehme RE, et al. Viral dynamics for LDT (Telbuvidine) treated Hepatitis B patients: high degree of initial inhibition with dose-dependent second phase HBV clearance suggests a new model for HBV dynamics [abstract]. Hepatology 2004; 40 Suppl. 1: 246A
50. Lai CL, Brown N, Myers M, et al. Valtorcitabina provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: results of a phase I/II clinical trial. J Hepatol 2004; 40 Suppl. 1: 173A
51. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: the final solution? Hepatology 2000; 32: 430-2
52. Mailliard ME, Gollan JL. Suppressing hepatitis B without resis-tance: so far, so good. N Engl J Med 2003; 348: 848-50
53. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87-10652